Tradingtipp Celsion von 8 auf 1,2$ nun Rebound auf 2$? - 500 Beiträge pro Seite

[printguru]

schaut euch dieses Teil einmal an könnte interessant werden die kommenden Tage heute der erste Tag mit einem ordentlichen+ von aktuell 16% auf 1,5$ mit großem Volumen

Ich hoffe heute gegen Handelsende auf eine ordentliche Kaufwelle die den Kurs bis auf 1,55-1,65$ bringt und mit etwas Glück sehen wir morgen schon die 2$.


LG Printi

vieleicht gelingt mir hier ja wieder ein netter Zock der einige $$$einbringt

[printguru]

wichtig wäre daß die 1,5$ fallen dann gibt es einen ordentlichen Schub

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.535 von printguru am 11.02.13 21:20:32

....und durch.........

[printguru]

Antwort auf Beitrag Nr.: 44.128.565 von Market-Insider am 11.02.13 21:29:36

Hallo Market bist auch mal wieder mit dabei?

auf der 1,51 und 1,52 sind noch fette Bremsasks positioniert wenn die gegen Handelsende fallen würde wäre supper

Lg.Printi

[printguru]

Antwort auf Beitrag Nr.: 44.128.565 von Market-Insider am 11.02.13 21:29:36

nun 1,51-1,52

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.641 von printguru am 11.02.13 21:48:53

...kann wohl nur bedeuten das im grossen Stil akkumuliert wird.....
Schaun mer mal was geht.

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.641 von printguru am 11.02.13 21:48:53

es geht weiter..

[printguru]

Antwort auf Beitrag Nr.: 44.128.565 von Market-Insider am 11.02.13 21:29:36

1,52$ auch weckgekauft das kann jetzt was werden

1,52-1,53

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.641 von printguru am 11.02.13 21:48:53

geht doch..

Lg. MI

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.663 von printguru am 11.02.13 21:52:06

http://www.nasdaq.com/symbol/clsn/real-time#.URlcT2dvCSo

[printguru]

Antwort auf Beitrag Nr.: 44.128.686 von Market-Insider am 11.02.13 22:00:59

sieht fein aus genau auf Tageshoch geschlossen


1,54$ bin gespannt ob wir morgen schon mit 1,6-1,65$ eröffnen und dann pfeilsgerade auf 1,95-2$


LG. Printi

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.698 von Market-Insider am 11.02.13 22:02:45

http://www.nasdaq.com/symbol/clsn/after-hours#.URleYmdvCSo

[printguru]

Antwort auf Beitrag Nr.: 44.128.747 von Market-Insider am 11.02.13 22:11:41

ja ich habs gerade gesehen nachbörslich stehen wir schon bei 1,56$


bin zufrieden scheint ein lohnender Zock zu werden

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.721 von printguru am 11.02.13 22:06:21

ein Scheunentor großes GAP gilt es zu schließen...


Ich denke wir werden auch morgen wieder mit einem Sprung eröffnen.

[Elrond]

spielt ihr Zwei hier ein Doppel .....

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.769 von Elrond am 11.02.13 22:15:53

nee jtzt nicht mehr............

[Market-Insider]

Antwort auf Beitrag Nr.: 44.128.775 von Market-Insider am 11.02.13 22:17:19

kaufe ein e

[printguru]

Antwort auf Beitrag Nr.: 44.128.769 von Elrond am 11.02.13 22:15:53

wir motivieren uns gegenseitig

Und das macht einfach Spaß wenn der Kurs so schön nach oben zieht
Und das wird morgen erst fein werden wenn die 1000ender im Minutentackt hereinflattern(bin natürlich mit den entsprechenden St. dabei)

Übrigens wir stehen bei 1,57$ mit schönem Volumen nachbörslich
So macht Börse Spaß


LG Printi

[printguru]

nachbörslich 1,6$

Sollte hinhauen mit einem Eröffnungskurs zwischen 1,6-1,65$ wenn nicht gar 1,65-1,7$


So und nun ab ins Bett


LG Printi

[printguru]

neuer Tag neues Glück


Ich wünsche allen einen guten Morgen

[Market-Insider]

Antwort auf Beitrag Nr.: 44.129.745 von printguru am 12.02.13 10:05:22

Guten Morgen alle zusammen.

Ich werde das Glück nicht all zu sehr herausfordern. Habe bereits eine Verkaufsorder jehnseits der 1,30 € gesetzt. Ich denke heute kommt nochmals ein kräftiger Schub. Gestern auf Tageshoch geschlossen. Nachbörslich bis 1,60 USD gehandelt.

Möglich das die Verkaufsorder viel zu niedrig angesetzt wurde.

Keine Kaufs- oder Verkaufsaufforderung.

[Market-Insider]

Antwort auf Beitrag Nr.: 44.129.924 von Market-Insider am 12.02.13 10:39:19

http://www.nasdaq.com/symbol/clsn/after-hours?page=2#.URoOV2…



Ich rechne mit einem weiteren Gaap up.....

[willblueauf10]

Morgen.warum ging's hier so steil nach unten?

[printguru]

Antwort auf Beitrag Nr.: 44.130.205 von willblueauf10 am 12.02.13 11:26:49

desshalb

Celsion plunges 80 percent as liver cancer therapy fails trial
inShare0Share this
Email
Print
Related NewsKeryx kidney disease drug meets late-stage trial goal
Mon, Jan 28 2013
Bristol profit tops forecast; outlook is scaled back
Thu, Jan 24 2013
Lilly stomach cancer drug extends survival vs placebo
Tue, Jan 22 2013
CORRECTED-Lilly stomach cancer drug extends survival vs placebo -study
Tue, Jan 22 2013
Lilly drug chosen for U.S.-sponsored Alzheimer's trial
Fri, Jan 18 2013Related TopicsHealth »
Hot Stocks »
Asian Markets »
Thu Jan 31, 2013 11:36am EST

(Reuters) - Celsion Corp shares plunged by more than 80 percent after a late-stage study of the company's experimental liver cancer treatment ThermoDox failed to meet the main goal of increasing patients' survival without worsening their cancer.

The stock fell to a low of $1.41 before recovering slightly to trade at $1.46 on heavy volume on the Nasdaq on Thursday.

"I don't believe the data will support (marketing) registration in any of the major markets," Celsion Chief Executive Michael Tardugno said on a conference call.

The trial, named HEAT, consisted of 701 patients across 11 countries and was designed to show a 33 percent improvement in progression-free survival.

Celsion said it was conducting additional analyses of data from the trial to assess the future value of ThermoDox.

Patients on the control arm performed about 20 percent better than expected whereas those on ThermoDox performed worse than anticipated, Roth Capital Partners analyst Joseph Pantginis said, quoting the company.

"We are disappointed by the failure of the HEAT study and we highlight the increased risk around the company's pipeline which is driven by ThermoDox," he said.

ThermoDox is also being tested in mid-stage studies as a drug-delivery method for breast and colorectal cancers.

Celsion CEO Tardugno said the company will continue enrolling patients in the mid-stage breast cancer study.

ThermoDox utilizes a liposome -- a tiny bubble composed of lipids -- as a vehicle to transport a commonly used chemotherapy drug called doxorubicin, directly to the tumor.

Localized heat releases doxorubicin, depositing it in and around the tumor, maximizing the effect of the medication.

The liver-cancer study compared the HEAT results against patients treated with a procedure where tumors are destroyed using electricity, otherwise called radiofrequency ablation.

Pantginis downgraded Celsion's rating to "neutral" from "buy" and slashed his price target on the stock to $1.70 from $10, saying the target is now based solely on the mid-stage study of ThermoDox in breast cancer.

Celsion said it had sufficient cash to cover its expenses well into 2014. It has unaudited cash and investments of about $27 million.

CEO Tardugno said the company will review its colorectal cancer trial in the context of the HEAT results and then decide on whether to continue with the study.

(Reporting By Pallavi Ail in Bangalore; Editing by Roshni Menon and Sreejiraj Eluvangal)


http://www.reuters.com/article/2013/01/31/us-celsion-study-t…

[printguru]

Antwort auf Beitrag Nr.: 44.130.546 von printguru am 12.02.13 12:30:40

in schlechtem Deutsch


Reuters) - Anteile von Celsion Corp., die durch mehr als 80 Prozent nach einer spät-stufigen Studie der experimentellen Leber-Krebs-Behandlung der Gesellschaft ThermoDox getaucht sind, haben gescheitert, die Hauptabsicht zu entsprechen, das Überleben von Patienten zu vergrößern, ohne ihren Krebs schlechter zu machen.

Das Lager ist zu einem niedrigen von 1.41 $ vor der Besserung ein bisschen gefallen, um an 1.46 $ auf dem schweren Volumen auf dem Nasdaq am Donnerstag zu handeln.

"Ich glaube nicht, dass die Daten (Marketing) Registrierung auf einigen der Hauptmärkte unterstützen werden," hat der Celsion leitende Angestellte Michael Tardugno auf einem Konferenzgespräch gesagt.

Die Probe, genannt HITZE, hat aus 701 Patienten über 11 Länder bestanden und wurde entworfen, um eine 33-Prozent-Verbesserung im Überleben ohne Fortschritte zu zeigen.

Celsion hat gesagt, dass es zusätzliche Analysen von Daten von der Probe führte, um den zukünftigen Wert von ThermoDox zu bewerten.

Patienten auf dem Kontrollarm haben um ungefähr 20 Prozent besser geleistet als erwartet, wohingegen diejenigen auf ThermoDox schlechter geleistet haben als vorausgesehen, hat Kapital-Partneranalytiker von Roth Joseph Pantginis gesagt, die Gesellschaft zitierend.

"Wir sind durch den Misserfolg der HITZE-Studie enttäuscht, und wir heben die vergrößerte Gefahr um die Rohrleitung der Gesellschaft hervor, die von ThermoDox gesteuert wird," hat er gesagt.

ThermoDox wird auch Mitte stufige Studien als eine Methode der Rauschgift-Übergabe für den Busen und die colorectal Krebse geprüft.

Celsion CEO Tardugno hat gesagt, dass die Gesellschaft fortsetzen wird, Patienten Mitte stufige Brustkrebs-Studie einzuschreiben.

ThermoDox verwertet einen liposome - eine winzige Luftblase, die aus lipids zusammengesetzt ist - wie ein Fahrzeug, um ein allgemein verwendetes Chemotherapie-Rauschgift zu transportieren, doxorubicin direkt zur Geschwulst genannt hat.

Lokalisierte Hitze veröffentlicht doxorubicin, es in und um die Geschwulst ablegend, die Wirkung des Medikaments maximierend.

Die Studie des Leber-Krebses hat sich verglichen die HITZE-Ergebnisse gegen Patienten haben mit einem Verfahren behandelt, wo Geschwülste mit der Elektrizität, sonst genannt radiofrequency ablation zerstört werden.

Pantginis hat die Schätzung von Celsion zum "neutralen" davon degradiert "kaufen" und hat sein Preisziel auf dem Lager zu 1.70 $ von 10 $ aufgeschlitzt, sagend, dass das Ziel jetzt allein auf der Mitte stufige Studie von ThermoDox in Brustkrebs basiert.

Celsion hat gesagt, dass es genügend Bargeld hatte, um seine Ausgaben gut in 2014 zu bedecken. Es hat Bargeld und Investitionen von ungefähr $ 27 Millionen unrevidiert.

CEO Tardugno hat gesagt, dass die Gesellschaft seine colorectal Krebs-Probe im Zusammenhang der HITZE-Ergebnisse nachprüfen und sich dann entscheiden wird, ob man mit der Studie weitermacht.

(Der Bericht durch Pallavi kränkelt in Bangalore; das Redigieren durch Roshni Menon und Sreejiraj Eluvangal)

[printguru]

gestern kam denn folgender Artikel desshalb wohl auch der Kursanstieg


Celsion Corp. Free Analyst Research


By eTeligis
Feb 11, 2013 6:07:43 AM PST


Home
Articles (929)

Send MessageAdd to ContactsFollow


Biotech stocks have a precarious life. A single negative drug trial can send the stock price into a tizzy and vice versa. While Peregrine Pharmaceuticals Inc. recently completed the review of its Non-Small lung cancer drug and consequently saw its stock price skyrocketing, the opposite happened in the case of Celsion Corp. (NASDAQ:CLSN) whose stock took a dive following its unexpected results from Thermodox. However, Celsion Corp. still has the potential to bounce back. Being a member of St Bulls give you the exclusivity to speak with an analyst today. So, sign now for free at

www.stbulls.com

Celsion Corp. is currently reeling under the pressure of recent unfavorable results from the phase III trials of its drug candidate Thermodox. The drug is being developed for treating hepatocellular carcinoma. The drugs Phase III was started in 2008 and since then it has been the main catalyst for driving the stock price up. However, in January 2013, Celsion Corp. announced that the Phase failed to meet the endpoint, triggering a decline in stock price. However, it is too early to completely write off Thermodox. Get more insight about CLSN by signing up now at

www.stbulls.com


On the positive side, the company still has enough cash reserves to cover its operating expenses through 2013. As per the demands of the situation, the company is also evaluating alternatives beyond Thermodox. A biotech stock is generally written off, when its research process is completely abandoned. Using this criterion, there is still hope for Celsion Corp. as the company is likely to go ahead with the drug trials. While its Phase III trial did not show the desired results, it reinforced the point that the drug is safe, which keeps the avenues still open for the drug. ThermoDox is also still being tested for Corectal Cancer and Breast Cancer. Talk to our analysts and get their take on CLSN by registering now at

www.stbulls.com

The stock lost more than 80 percent of its value post-Thermodox fiasco. Technically, the stock looks weak at this point. Celsion Corp. is trading below its 5 days EMA of $1.63. It is also below its longer term 20 days EMA of $4.56, showing very bearish trend. Based on technical indicators, the stock may tumble down to $1.23 in the coming trading session. However, it is highly likely that the stock may see some relief rally. In such case, its first resistance level is at $1.67, breaching which the stock may even go as high as $2.57. Find out why we initiated coverage on CLSN before the masses do by registering at

www.stbulls.com


Disclaimer: Bull Market Group LTD is not a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security. A third party, Stbulls.com has paid Bull Market Group LTD four hundred and fifty dollars for the publication of this news release. Neither Bull Market Group LTD nor the hiring party has a financial relationship with any company whose stock is mentioned in this release.


Contact Person:


Martin Peters

Marketing Consultant

[e-mail]






Associated Documentation:

Link to submission on http://www.eteligis.com
StBulls.com_-_2-11-2013_DVH_2_ETL.docx
Copyright eTeligis Inc. 2013. All rights reserved.

Advertisement



When was the last time you made 530% on a three day trade? Our subscriber, Maxine Brand, a small business owner in Charlotte, N.C. told us she made a three day +530% gain on one of our recommendations in October. And over the past three years, we’ve seen quick gains of +310%, +250% and +287% on individual stocks. Not bad for a free service. Click here to get our single best trading idea every week...


Advertisement

http://www.smallcapnetwork.com/Celsion-Corp-Free-Analyst-Res…

[printguru]

Antwort auf Beitrag Nr.: 44.130.623 von printguru am 12.02.13 12:41:58

und das selber wieder übersetzt in schlechtem Deutsch

Celsion Corp. freie Analytiker-Forschung


Durch eTeligis
Am 11. Feb. 2013 06:07:43 PST
Haus
Artikel (929)

Senden Sie MessageAdd an ContactsFollow

Lager von Biotech haben ein unsicheres Leben. Eine einzelne negative Rauschgift-Probe kann den Aktienpreis in eine Aufregung und umgekehrt senden. Während Peregrine Pharmaceuticals Inc. kürzlich die Rezension seines Nichtkleinen Lungenkrebs-Rauschgifts vollendet hat und folglich seinen Aktienpreis gesehen hat, das Gegenteil sprunghaft ansteigen, das im Fall von Celsion Corp. (NASDAQ:CLSN) zufällig ist, dessen Lager ein Tauchen im Anschluss an seine unerwarteten Ergebnisse von Thermodox genommen hat. Jedoch hat Celsion Corp. noch das Potenzial, um zurück zu springen. Ein Mitglied St. Bulls zu sein, gibt Ihnen die Exklusivität, um mit einem Analytiker heute zu sprechen. Also, Zeichen jetzt umsonst daran

www.stbulls.com

Celsion Corp. taumelt zurzeit unter dem Druck von neuen ungünstigen Ergebnissen von den Proben der Phase III mit seinem Rauschgift-Kandidaten Thermodox. Das Rauschgift wird entwickelt, um hepatocellular Krebsgeschwür zu behandeln. Die Rauschgift-Phase III wurde 2008 angefangen, und seitdem ist es der Hauptkatalysator gewesen, für den Aktienpreis in die Höhe zu treiben. Jedoch, im Januar 2013, hat Celsion Corp. bekannt gegeben, dass die Phase gescheitert hat, den Endpunkt zu entsprechen, einen Niedergang im Aktienpreis auslösend. Jedoch ist es zu früh, um Thermodox völlig abzuschreiben. Bekommen Sie mehr Scharfsinnigkeit über CLSN, indem Sie sich jetzt daran verpflichten

www.stbulls.com


Auf der positiven Seite hat die Gesellschaft noch genug Barreserven, um seine Betriebskosten im Laufe 2013 zu bedecken. Laut der Anforderungen der Situation bewertet die Gesellschaft auch Alternativen außer Thermodox. Ein biotech Lager wird allgemein abgeschrieben, wenn sein Forschungsprozess völlig aufgegeben wird. Mit diesem Kriterium gibt es noch Hoffnung für Celsion Corp., weil die Gesellschaft wahrscheinlich mit den Rauschgift-Proben weitermachen wird. Während seine Probe der Phase III die gewünschten Ergebnisse nicht gezeigt hat, hat es den Punkt verstärkt, dass das Rauschgift sicher ist, der die Alleen behält, noch öffnen sich für das Rauschgift. ThermoDox wird auch noch für Corectal Krebs und Brustkrebs geprüft. Sprechen Sie mit unseren Analytikern und bekommen Sie ihren, auf CLSN genommen, indem Sie sich jetzt dabei einschreiben
www.stbulls.com

Das Lager hat mehr als 80 Prozent seines Werts post-Thermodox Misserfolg verloren. Technisch sieht das Lager schwach auf diesen Punkt aus. Celsion Corp. tauscht unter seinen 5 Tagen EMA von 1.63 $. Es sind auch unter seinem längeren Begriff 20 Tage EMA von 4.56 $, sehr bärenhafte Tendenz zeigend. Gestützt auf technischen Hinweisen kann das Lager zu 1.23 $ in der Ankunft Handelssitzung hinunterstürzen. Jedoch ist es hoch wahrscheinlich, dass das Lager eine Erleichterung sehen kann sich sammeln. In solchem Fall ist sein erstes Widerstand-Niveau an 1.67 $, durchbrechend, der das Lager sogar nicht weniger als 2.57 $ gehen kann. Finden Sie heraus, warum wir Einschluss auf CLSN begonnen haben, bevor die Massen durch das Registrieren dabei tun

www.stbulls.com


Verzichterklärung: Bull Market Group LTD ist nicht ein eingetragener Investitionsberater, und nichts in diesem Bericht ist als ein Ansuchen beabsichtigt, um jede Sicherheit zu kaufen oder zu verkaufen. Ein Dritter, hat Stbulls.com Haussemarkt Gr bezahlt


Klingt doch garnicht so schlecht und sollte hier auch nur etwas positives rauskommen stehen wir wohl ganz ganz schnell bei 3-5$

Lg Printi

[franzisca]

Zitat von printguru: schaut euch dieses Teil einmal an könnte interessant werden die kommenden Tage heute der erste Tag mit einem ordentlichen+ von aktuell 16% auf 1,5$ mit großem Volumen

Ich hoffe heute gegen Handelsende auf eine ordentliche Kaufwelle die den Kurs bis auf 1,55-1,65$ bringt und mit etwas Glück sehen wir morgen schon die 2$.


LG Printi

vieleicht gelingt mir hier ja wieder ein netter Zock der einige $$$einbringt

Reicht Dir ein Thread nicht!


Celsion Corporation - Common Stock
1.65
0.11 6.67%
Range: 0.00 - 0.00
Open: 0.00
Vol: 7,000

Bid: 1.63 Ask: 1.55 Size: 21 x 5

[printguru]

Antwort auf Beitrag Nr.: 44.130.771 von franzisca am 12.02.13 13:07:36

Ich eröffne des öfteren einen Tradingtipp Thread wo es nur darum geht Titel hervorzuheben die ein supper Momentum haben und ein dementsprechend hohes Volumen aufweisen um mit einer ordentlichen Summe zu agierenEs geht darum 10-50% in einem oder wenigen wenigen Tagen einzufahren und dann lasse ich einen Teil der Aktien noch länger laufen so wie es hier der Fall sein wird in anderen Fällen wo es nur um einen Zock geht verkaufe ich hingegen alle meine St.

Desshalb auch Tradingtipp und nicht Investitionstipp

Ich wäre froh wenn auch andere WO.Mitglieder sólche Aktien hervorheben würden wo das Momentum sehr stark ist leider werden meist Aktien empfohlen die man längerfristig behalten sollte und an die Geschichte glauben muß und meistens geht dann der Schuß nach hinten los


Hier kann noch einiges gehen heute muß es aber nicht aber das Risiko ist überschaubar wenn man mit einem Stopp agiert für die Tradingposi. die St. die ich langfristig von Celsion behalten will bleiben im Depotund mit den anderen wird gezockt

LG Printi

[printguru]

so muß kurz etwas eledigen.Wir sehen uns um 15:25

würde mich freuen wenn wir schon zur Eröffnung schön im grünen Bereich sein würden


bis gleich

[franzisca]

Antwort auf Beitrag Nr.: 44.131.016 von printguru am 12.02.13 13:56:26

War mir schon klar, bin ja auch seit Freitag dabei aber wenig Zeit da ich auch noch einen Job habe.

[printguru]

ging jetzt leidereinmal daneben bin zu 1,45$ ausgesoppt worden

halte aber noch meine St. die ich zu 1,22$ gekauft habe

Zock ist somit diesesmal nicht aufgegangen.

LG Printi


bis zum nächstenmalund dann folgt auf diesen kleinen Verlust hoffentlich wieder ein fetter Gewinn

[zuzlhuba]

http://www.nasdaq.com/article/free-research-report-on-nii-ho…

[zuzlhuba]

http://www.nasdaq.com/article/celsion-corporation-announces-…
Celsion Corporation Announces $15 Million Registered Direct Offering
By PR Newswire, February 22, 2013, 09:15:00 AM EDT Vote up




LAWRENCEVILLE, N.J., Feb. 22, 2013 /PRNewswire/ -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has received commitments from institutional investors to purchase an aggregate of $15 million of the Company's securities in an at-the-market registered direct offering, led by a dedicated health care fund.

The Company entered into definitive purchase agreements with these investors pursuant to which the Company agreed to sell an aggregate of 15,000 shares of its zero coupon preferred stock (which are convertible into a total of approximately 12.1 million shares of common stock) and warrants potentially exercisable for up to approximately 6.0 million additional shares of its common stock. In addition to the preferred stock not having a required dividend right, the preferred stock will not have any preferences over the Company's common stock, including no liquidation preference rights. Subject to certain ownership limitations, the preferred stock is convertible at any time at the option of the holder into shares of common stock at a conversion price of $1.2425 (which represents $0.0625 above $1.18, the closing bid price of the common stock on the previous trading day). The warrants will be exercisable at a price of $1.18 per share and will expire five years from the issuance date. The closing of the offering is expected to take place on or about February 27, 2013, subject to the satisfaction of customary closing conditions.

The estimated net proceeds to the Company from the offering are expected to be approximately $13.8 million. With the net proceeds from this offering, the Company projects to have an unaudited cash and investment balance of approximately $47 million. The Company intends to use the net proceeds from this offering for general corporate purposes.

Dawson James Securities, Inc. acted as exclusive placement agent in connection with the offering.

A shelf registration statement (File No. 333-183286) relating to the shares of preferred stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the preferred stock exercise of the warrants) has been filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the offering will be filed by the Company with the SEC. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov, from Dawson James Securities by e-mailing [e-mail], or from Celsion Corporation, 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648, Attention: Investor Relations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in this offering. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Additional Information:

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, but not limited to, the amount and use of proceeds the Company expects to receive from the offering, the closing of the offering, the conversion of the preferred stock and the exercise of the warrants. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate, and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Forward-Looking Statements" and "Risk Factors" in the Company's Annual Reports on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Senior Vice President - Corporate

Strategy and Investor Relations

609-482-2455

[e-mail]

SOURCE Celsion Corporation

[zuzlhuba]

http://seekingalpha.com/article/1261421-celsion-has-multi-ba…

[bmuesli]

Celsion Corporation Provides Business Update
By PR Newswire, April 23, 2013, 08:00:00 AM EDT Vote up




HEAT Study Analysis Shows ThermoDox® Improves Progression Free Survival (PFS) and Overall Survival (OS) when Heating is Optimized
Cash Conservation Program Facilitates the Company's Strategic Options
Engagement of Financial Advisor Assists in Evaluation of Acquisition Opportunities
LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts. This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint. Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA. The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®. These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients. This data is subject to further verification and review by the HEAT Study Steering Committee.

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys, Celsion's Vice President and Chief Medical Officer. "These data are very exciting and consistent with the mechanism of ThermoDox® activity."

Michael Tardugno, Celsion's Chief Executive Officer, added, "Based on the strength of these findings, the Company will request a meeting with regulatory authorities for guidance on moving forward with our HCC development program. We plan to disclose the details of the HEAT Study data at upcoming medical meetings and in a peer-reviewed publication. We will provide updates on these activities when appropriate."

Corporate Restructuring

The Company implemented a restructuring program to lower its operating costs to conserve capital. The program includes elimination of approximately one-third of Celsion's workforce and the deferral of expenses associated with the Company's Phase II study of ThermoDox® in combination with RFA for the treatment of colorectal liver metastases (The ABLATE Study). Celsion expects these measures to remain in effect until such time as it finalizes its plans for the continuation of its development program with ThermoDox® in HCC. Celsion ended the first quarter of 2013 with approximately $46 million in cash and investments. Ongoing salary costs, net of restructuring costs, are expected to reduce overall operating expenses during the current fiscal year.

"While it is difficult to eliminate positions in our talented and dedicated workforce, this move is necessary to ensure that our costs are adequately aligned with our resources and business strategy," Mr. Tardugno said. "We are reducing expenses in all areas, but we are doing this with an eye toward limiting the impact on our future development programs for ThermoDox® as well as afford us the opportunity to identify and develop new product candidates."

Engagement of Financial Advisor to Evaluate Acquisition Alternatives

The Company has engaged Cantor Fitzgerald & Co. to conduct a comprehensive review of merger and acquisition opportunities with the goal of identifying novel products with high potential, or companies, for Celsion to acquire. Strategic alternatives the Company may pursue could include, but are not limited to, continuing its current operating plan, partnering or other collaboration agreements, acquisition of another company's business or assets, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Sr. Vice President - Corporate

Strategy and Investor Relations

609-482-2455

[e-mail]

SOURCE Celsion Corporation



This article appears in: News Headlines

Referenced Stocks: CLSN




Latest News Video

Rescue Efforts Continue in Quake-St...
Woman Comes Face To Face With A Tig...
TSA Delays Allowing Pocketknives On...


Login Comments (0)Login or signupYou must be logged in to commentType your comment here...
0/2500 characters

Markers:Tags:

+ Photo
Follow Conversation PostSort By: Most RecentPopular NowMost LikesOldest First
No items at this time...
social networking by


Related stocks Articles
Rent-A-Center's Earnings Misses Est. - Analyst Blog
Apr 23, 2013 Packaging Corporation's Earnings Zoom - Analyst Blog
Apr 23, 2013 Company News for April 23, 2013 - Corporate Summary
Apr 23, 2013 Sign-in
Existing NASDAQ.com member? Log in here.
By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

Welcome back: Log in using your: Account Switch Accounts From Our Trusted News Source


Highest Rated Articles of the Last Week
This Time It's Macau, Baby!!
The Goldman Sachs Standard (GS)
NQ Mobile's NQSky Named Finalist in the 2013 Hot Companies and Best Products Awards by Network Products Guide
BlackBerry is Back From the Dead

View All




Most Active by Volume:
Company Last Sale Change Net / %
BAC $ 11.9945 0.27 2.34%
MSFT $ 30.755 0.08 0.24%
QQQ $ 69.365 0.58 0.84%
INTC $ 22.98 0.10 0.44%
GE $ 21.425 0.08 0.35%
S $ 7.17 unch
ACI $ 4.605 0.29 5.83%
COH $ 56.15 5.56 10.99%
View more in Most Active



About NASDAQ OMX
NASDAQ OMX Technology
NASDAQ OMX Listing Center
Investor Relations
Public Policy Advocacy
Join Our Community
Sitemap
Advertise With Us
Feedback
Terms of Use
Privacy Statements
Contact
Annual Reports
Careers
Follow us on Twitter Like us on Facebook Subscribe to our RSS Feed

Read more: http://www.nasdaq.com/article/celsion-corporation-provides-b…

[bmuesli]

http://seekingalpha.com/article/1389731-celsion-s-a-fighter?…

[franzisca]

[bmuesli]

http://www.nasdaq.com/article/celsion-corporation-to-hold-fi…


Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013


By PR Newswire, May 01, 2013, 08:00:00 AM EDT


Vote up








LAWRENCEVILLE, N.J., May 1, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today announced that it would hold a conference call to discuss first quarter 2013 results at 11:00 a.m. EDT on Thursday, May 9, 2013. To participate in the call, interested parties may dial 1-888-329-8862 (Toll-Free/North America) or 1-719-325-2376 (International/Toll) and ask for The Celsion Corporation First Quarter 2013 Financial Results Conference Call to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Thursday, May 9, 2013 at 2:00 p.m. EDT and will remain available until Thursday, May 23, 2013. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 2227568. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2:00 p.m. EDT on Thursday, May 9, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Sr. Vice President - Corporate Strategy &

Investor Relations

609-482-2455

[e-mail]

SOURCE Celsion Corporation



This article appears in: News Headlines


Referenced Stocks: CLSN


Read more: http://www.nasdaq.com/article/celsion-corporation-to-hold-fi…

[bmuesli]

http://www.nasdaq.com/article/celsion-announces-thermodox-he…


Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013


By PR Newswire, May 01, 2013, 08:00:00 AM EDT


Vote up








LAWRENCEVILLE, N.J., May 1, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for Celsion's Phase III HEAT Study and Ronnie T.P. Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion's Phase III HEAT Study will, in conjunction with their scientific presentations, review the clinical trial results including new emerging findings from the HEAT Study post hoc analysis at the 9th Annual Meeting of the World Conference on Interventional Oncology, which is being held May 16 - 20, 2013 in New York City. The Company recently reported, based on the post hoc analysis, that ThermoDox® in combination with radiofrequency ablation (RFA) markedly improved progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA. Dr. Lencioni's presentation, titled "Advances in Image-Guided Ablation" will be held Thursday, May 16, 2013 at 11:00 a.m. EDT in Plenary Session: Multidisciplinary State-of-the Art: HCC and Professor Poon's presentation, titled "Thermally Sensitive Drug Carriers" will be held Thursday, May 16, 2013 at 4:30 p.m. EDT in Concurrent Session: New Drugs/New Carriers/New Devices.

Celsion has conducted a comprehensive analysis of the data from the Phase III HEAT Study of ThermoDox® in hepatocellular carcinoma (HCC) with key principal investigators, data experts and liver cancer experts including Professors Lencioni and Poon. This analysis followed the announcement on January 31, 2013, that ThermoDox® in combination with RFA did not meet the Study's primary endpoint. Emerging data from the HEAT Study post hoc analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.

"The HEAT Study is the largest clinical trial ever conducted in the field of image-guided ablation of HCC; as such, there is a trove of important data emerging from this study regarding the use of ThermoDox® in conjunction with RFA to treat this serious, deadly cancer," said Professor Lencioni. "I am pleased to introduce this analysis of a large subgroup which may be indicating a meaningful clinical benefit in both PFS and overall survival at WCIO. The details of the data will be presented for peer review at upcoming scientific meetings. It is important to note that the duration of heat from the RFA procedure appears to be a key factor in a successful clinical outcome when combined with ThermoDox® as suggested by this analysis. These findings are consistent with our understanding of how RFA plus ThermoDox® can potentially offer an important new treatment for this underserved patient population."

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.


Investor Contact

Jeffrey W. Church

Sr. Vice President - Corporate

Strategy and Investor Relations

609-482-2455

[e-mail]

SOURCE Celsion Corporation



This article appears in: News Headlines


Referenced Stocks: CLSN




Read more: http://www.nasdaq.com/article/celsion-announces-thermodox-he…

[bmuesli]

Antwort auf Beitrag Nr.: 44.583.531 von bmuesli am 07.05.13 16:42:44

ob uns da Mitte Mai gute News erwarten?

[bmuesli]

http://www.nasdaq.com/article/celsion-corporation-reports-fi…

Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update


By PR Newswire, May 09, 2013, 08:00:00 AM EDT


Vote up








Company to Hold Conference Call on Thursday, May 9, 2013 at 11:00 a.m. ET

LAWRENCEVILLE, N.J., May 9, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer. ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer, The DIGNITY Study.

Following the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the HEAT Study's primary endpoint, the Company conducted a comprehensive analysis of the data from the Study which was reviewed by its key principal investigators as well as liver cancer and clinical data experts. These emerging findings from the HEAT Study suggest that RFA dwell time had a positive impact on progression free survival (PFS) and overall survival (OS) in patients treated with ThermoDox® plus RFA when compared to the control group. This analysis was conducted in a sizable patient subgroup. These findings will be discussed by two of the HEAT Study's lead investigators at scientific sessions of the World Conference on Interventional Oncology on May 16, 2013. Celsion's lead investigators agree that these are interesting findings which should be further pursued.

"With the support of our medical advisors, we have been working diligently to better understand the clinical data and findings from the Phase III HEAT Study. Concurrently, we have been taking appropriate measures to position Celsion for future success including reducing expenses and exploring acquisition opportunities," said Michael Tardugno, Celsion's President and Chief Executive Officer. "At this point, we have concluded that emerging findings from our post hoc analysis of the HEAT Study provide a basis for review with various regulatory agencies and an opportunity to discuss a path forward for our HCC development program. Our recent expense reduction initiatives ensure a strong balance sheet as we explore opportunities to broaden our product pipeline and mitigate risk."

Recent Business Developments

During the first quarter of 2013, the Company raised $27 million in gross proceeds from several financing transactions as well as a new research and development collaboration:
•Celsion sold common stock through a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and received gross proceeds of approximately $7 million.
•Celsion entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 15,000 shares of its Series A 0% convertible preferred stock and warrants to purchase approximately 6.0 million shares of its common stock at an exercise price of $1.18 per share, for gross proceeds of $15 million.
•Celsion entered into a Technology Development Agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun) for ThermoDox® for the greater China territory. Under the terms of the agreement, Hisun paid Celsion a $5 million payment in support of ThermoDox® technology development.

In April 2013, the Company provided a comprehensive business update which included the following:
•Emerging findings from the HEAT Study post hoc analysis suggests that ThermoDox® markedly improved progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA. The post hoc analysis indicated that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®. These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.
•The Company implemented a restructuring program to lower its operating costs to conserve capital. The program included the elimination of approximately one-third of Celsion's workforce and the deferral of expenses associated with the Company's Phase II study of ThermoDox® in combination with RFA for the treatment of colorectal liver metastases (The ABLATE Study).
•The Company engaged Cantor Fitzgerald & Co. to conduct a comprehensive review of merger and acquisition opportunities with the goal of identifying novel products with high potential, or companies, for Celsion to acquire.

Financial Results

For the quarter ended March 31, 2013, Celsion reported a net loss of $651,000 compared to a net loss of $6.2 million in the same period of 2012. Net loss for the quarter ended March 31, 2013 was favorably impacted by lower operating costs coupled with the non-cash benefit of $4.3 million from the valuation of the common stock warrant liability associated with warrants issued in a registered direct equity offering in September 2009. Also in the first quarter of 2013, the Company entered into a Technology Development Agreement with Hisun, which included a payment of $5 million from Hisun, to support technology development transfer of ThermoDox® in the China territory. The first quarter income statement was also impacted by a one-time, non-cash deemed dividend from the beneficial conversion feature of $4.6 million on the preferred stock issued in February 2013, resulting in a net loss attributable to common shareholders of $5.3 million.

For the quarter ended March 31, 2013, net cash provided by operations was $1.8 million. During the first quarter of 2013, the Company raised $20.8 million in new capital, net of issuance costs, from the sale of preferred stock to certain institutional investors, the sale of common stock under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., and the exercise of common stock warrants and options. The Company ended the current quarter with $45.9 million in cash, investments and accrued interest on short-term investments.

Research and development expenses decreased by $1.5 million (32%), from $4.7 million in the first quarter of 2012 to $3.2 million in the first quarter of 2013. This decrease was primarily due to reduced clinical development costs associated with the Phase III HEAT Study and activities related to the development of commercial manufacturing capabilities for ThermoDox®. General and administrative expenses of $1.7 million in the first quarter of 2013 were relatively flat as compared to the same period of 2012.

Quarterly Conference Call

The Company is hosting a conference call to provide a business update and discuss the first quarter 2013 results at 11:00 a.m. EDT Thursday, May 9, 2013. To participate in the call, interested parties may dial 1-888-329-8862 (Toll-Free/North America) or 1-719-325-2376 (International/Toll) and ask for The Celsion Corporation First Quarter 2013 Earnings Conference Call approximately ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on May 9, 2013 at 2:00 p.m. EDT and will remain available until May 23, 2013. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 2227568. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2:00 p.m. EDT Thursday, May 9, 2013.

About ThermoDox® and the Phase III HEAT Study

ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. ThermoDox® is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer. Localized mild hyperthermia (39.5 - 42 degrees Celsius) created by radiofrequency ablation (RFA) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor. On January 31, 2013, Celsion announced that ThermoDox® in combination with RFA did not meet the primary endpoint of the HEAT study in patients with hepatocellular carcinoma, also known as primary liver cancer. Celsion is conducting additional analyses of the data from the HEAT study to assess the future strategic value of ThermoDox®.

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and Hisun at any time; possible changes in cost and timing of development and testing, capital structure, financial condition, working capital needs and other financial items; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Senior Vice President - Corporate

Strategy and Investor Relations

609-482-2455

[e-mail]






Read more: http://www.nasdaq.com/article/celsion-corporation-reports-fi…

[bmuesli]

http://www.nasdaq.com/article/celsion--q1-13-earnings-confer…

[bmuesli]

http://seekingalpha.com/article/1419401-celsion-s-q1-call-wh…
Introduction and Q1 Earnings

I've been covering Celsion (CLSN) since the beginning of January 2012, when it was anticipating its Phase III results for ThermoDox with RFA (radio frequency ablation).

3,672 people received this article by email alert
Add your email to get alerts on CLSN too:
Get email alerts on CLSN »This article was sent to 284,823 people who get the Investing Ideas newsletter. Get the Investing Ideas newsletter »
ThermoDox is a unique liposomal delivery method of getting doxorubicin to the site of cancer tumors being treated. Preliminary trials looked great and the idea behind ThermoDox was one that made sense: delivering a concentration of an often-used cancer drug to the site of the tumor by its Liposomal transport system, and using heat to activate it en masse.

Celsion is evaluating ThermoDox in a Phase III clinical trial for primary liver cancer, as well as Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Celsion reported their Q1 results this morning, beating analyst estimates with an EPS of -$0.12 compared to estimates of -$0.16, and slightly missing revenue with a reported $125k versus analyst estimates of $190k. Its cash burn was down from $6.2 million in the first quarter of 2012 to $651,000 in the first quarter of 2013. The full earnings press release can be found here.

I wasn't expecting anything groundbreaking on the financial side of things, but was far more interested in the conference call and the executive's editorialization of things in the 11AM conference call this morning.

However, the real story lies not in the financials reported in quarter 1, but in the future of the company and the steps being taken by executives to ensure that the company does have a future.

After the post-Phase III crash, the company went through the mandatory "battening of the hatches", curbing costs, raising some rather dilutive financing, and pondering mergers and acquisitions to see that the fundamentals of the company remain strong should ThermoDox not work out.

Recently, the company reported that it had found a modicum of success with certain subgroups of ThermoDox when RFA had been applied for certain amounts of time.

On April 23rd of this year, Celsion reported that after a thorough review of its HEAT study, there was clear evidence that ThermoDox showed a "marked improvement" (company's words, not mine) when RFA is optimized. CEO Michael Tardugno commented:


Michael Tardugno, Celsion's Chief Executive Officer, added, "Based on the strength of these findings, the Company will request a meeting with regulatory authorities for guidance on moving forward with our HCC development program. We plan to disclose the details of the HEAT Study data at upcoming medical meetings and in a peer-reviewed publication. We will provide updates on these activities when appropriate."


Today's Conference Call

CEO Michael Tardugno led off the call today. The first thing the call covered was the Phase III HEAT study, following up on the post-hoc data Celsion found. Tardugno comments that the post-hoc analysis was done by one group that was involved in the initial HEAT study, as well as one independent group.

Tardugno did take a moment to remind investors that the post-hoc data is extremely speculative and not yet of any "statistical significance." Having said that, the call was littered with hints afterward about the potential benefits going forward.

It was repeated several times during the call, just as it was in its PR, that ThermoDox can markedly improve PFS in a "large subgroup" of patients.

Tardugno went on to comment that Celsion's data at its disclosed upcoming May 16th presentation will tell more, and will be subsequently posted on Celsion's website. He commented that Celsion was going to perform some limited trials and animal testing over the summer, and then plans on meeting with the FDA to discuss pursuing more clinical studies with regards to ThermoDox. He noted later in the call that Celsion wanst to be able to do this "well before the end of 2013".

In April, the company was restructured, eliminating one-third of the workforce, consisting mostly of contractors and consultants. Tardugno and others alluded to trimming the fat off of the company in order to maintain "bare bones" personnel. They noted that they can be effective with the personnel they have on board now, as they've operated like this in the past.

Celsion finished the quarter with $45.9 million cash and investments on hand, double what they had on hand after Q1 last year.

Tardugno repeated that they are very confident in their liposomal deliver technology, but are also exploring acquisitive potentials to mitigate the "all-in" risk on just focusing on technology.

CFO Greg Weaver offered a short update, noting there's 51.6 million shares of common stock outstanding, and that it's costing about $1 million a month to run the business as is.

Dr. Nick Borys followed, stating the review of the Phase III data started as soon as it was released. He noted that they determined early on that patients with smaller lesions had some obvious success. He used "marked improvement in PFS and survival" again, as Celsion used in their last press release.

Borys noted that longer RFA times were a factor and that they improved outcomes in all size tumors.

He stated that there is a "major" subgroup who appear to have benefit and that HEAT may be the foundation for the ultimate future success of ThermoDox.

VP of Corporate Strategy, Jeff Church, reaffirmed quickly that Celsion is working with Cantor Fitzgerald on acquisition candidates, and that they've identified about 10 potential targets already. He noted that these companies would have complimentary products and technologies that will help mitigate growth.

Tardugno ended by stating that the company is moving forward and focused on the future. He stated the company is still working with Phillips on RFA and is still confident in the non-invasive method of treating cancer using doxorubicin.

Conclusion

This seemed like a pretty good call to me. Celsion executives sounded confident about the future, and I'm satisfied with the cuts they've made and the corporate strategy they're using in response to the Phase III failure earlier this year. I'm staying long Celsion for the time being, with an eye on its upcoming May 16th presentation of ThermoDox data.

[berti40]

Mal sehen wo wir heute abend und morgen abend stehen!
:-))

[berti40]

Heute wird es spannend!!

[berti40]

News!!!!!
Und auch noch gute News.

[bmuesli]

See headlines for CLSN
View Print Version
More from PR Newswire Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013

Referenced Stocks CLSN71%Rate It

Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)


By PR Newswire, May 17, 2013, 08:00:00 AM EDT


Vote up








Duration of RFA Procedure Correlates with an Overall Survival Benefit

LAWRENCEVILLE, N.J., May 17, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for the HEAT Study and Professor Ronnie T.P. Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for the HEAT Study conducted separate scientific discussions reviewing the clinical trial results from the Company's Phase III HEAT Study including new emerging findings from the HEAT Study post-hoc analysis at the 9th Annual Meeting of the World Conference on Interventional Oncology, which is being held on May 16 to 20, 2013 in New York City. The new post-hoc findings suggest that optimized heating cycles markedly improve radiofrequency ablation (RFA) plus ThermoDox's potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes. Professors Poon and Lencioni both concluded that the findings warrant further investigation and development of ThermoDox as a first line treatment for HCC when combined with RFA. The slide presentations are available on the Events and Presentations page on the Celsion website.

"I was pleased to discuss this post-hoc analysis of a large subgroup of patients from the Phase III HEAT Study at the WCIO Conference in New York which may be indicating a meaningful clinical benefit in both PFS and Overall Survival in patients who received an optimized RFA procedure," said Professor Lencioni. "It would appear that the duration of heat from the RFA procedure is a key factor in a successful clinical outcome when combined with ThermoDox as suggested by this analysis. These findings may offer a path forward to potentially offering an important new therapy for HCC patients with limited treatment options."

"This subgroup analysis of approximately 300 patients, although not statistically significant, is nevertheless demonstrating a strong positive trend in both PFS and Overall Survival in ThermoDox® treated patients when heating cycles from the RFA procedure were optimized," said Professor Ronnie Poon. "What we have learned from the HEAT Study is that there is a large cohort of patients that appear to have demonstrated an important benefit from ThermoDox provided the RFA treatment time is properly applied. These findings are quite encouraging and should be confirmed with additional non-clinical studies and clinical trial data."

The data from the HEAT Study post-hoc analysis presented by Professors Lencioni and Poon demonstrate that ThermoDox markedly improves PFS and OS in patients with a single lesion if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesion regardless of size and represent a subgroup of approximately 300 patients or 42% of the patients in the HEAT Study. The post-hoc analysis completed by the Company to-date indicates that there may be a large patient cohort that benefited from RFA plus ThermoDox regardless of lesion size.
•In the patient subgroup treated in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes and was completed within 90 minutes (40% of single lesion patients), Overall Survival improved by 66% (Hazard Ratio of 0.602) when compared to the control arm of RFA treatment only.
•In the patient subgroup treated in the ThermoDox arm whose RFA procedure lasted longer than 90 minutes (23% of single lesion patients), Overall Survival almost doubled (Hazard Ratio of 0.508) when compared to the control arm of RFA treatment only.
•When combined, these two subgroups show clinical results that indicated a 53% improvement in Overall Survival, a Hazard Ratio of 0.65, and a Pvalue = 0.105.
•In contrast, the patient subgroup treated with ThermoDox whose RFA procedure lasted less than 45 minutes in duration (37% of single lesion patients) indicated that the control arm had an improved Overall Survival benefit when compared to the ThermoDox arm.
•The Hazard Ratios reported above should be viewed with caution since they are not statistically significant and the HEAT Study has not reached its median point for Overall Survival analysis. Celsion will continue following all patients enrolled in the HEAT Study to the secondary endpoint, Overall Survival, and update its subgroup analysis based on RFA heating duration.

Dr. Lencioni's presentation, titled "Advances in Image-Guided Ablation" was held in Plenary Session: Multidisciplinary State-of-the Art: HCC and Professor Poon's presentation, titled "Thermally Sensitive Drug Carriers" was held in Concurrent Session: New Drugs/New Carriers/New Devices. Both presentations were held on Thursday, May 16, 2013 and are available on the Company's website at www.celsion.com under "News & Investor Info - Events & Presentations."

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Sr. Vice President — Corporate

Strategy and Investor Relations

609-482-2455

[e-mail]

SOURCE Celsion Corporation



This article appears in: News Headlines


Referenced Stocks: CLSN


Read more: http://www.nasdaq.com/article/celsions-thermodox-heat-study-…

[bmuesli]

Hallo berti

habe gesehen daß du auch bei Ariva aktiv bist. Villeicht kannst du ja auch mal die News von heute dort reinstellen.

Danke

[bmuesli]

http://www.nasdaq.com/symbol/clsn/institutional-holdings/new

[bmuesli]

http://www.nasdaq.com/symbol/clsn/insider-trades/buys

[bmuesli]

http://www.nasdaq.com/symbol/clsn/short-interest

[bmuesli]

http://www.mdconferencefinder.com/

hier mal der Link Konferenz wo auch Celsion anwesend war. Villeicht findet ja noch jemand was interessantes.

[bmuesli]

weiß jemand hier wie so die Stimmung in den Amiboards zu Celsion ist?

[bmuesli]

http://seekingalpha.com/article/1402281-biotech-watchlist-20…

Werte mit explosivem Potential

[bmuesli]

http://celsion.com/

[bmuesli]

http://www.nasdaq.com/symbol/clsn/premarket

sieht nach steigendem Kurs aus.

[tbhomy]

In anderen Boards ist die Stimmung unterschiedlich, so wie es sich zwischen Shorties und Longies nun einmal immer darstellt.

http://investorshub.advfn.com/boards/board.aspx?board_id=158…

http://finance.yahoo.com/mb/forumview/?&bn=690bb330-e5e7-33e…

[sebirem]

das nenne ich Orgasmus Aktie Pur...

wer ist drinn?
wie lange bleibt ihr oder seit ihr nach dem heutigen Anstieg raus?

[printguru]

Ich bin noch immer von damals dabei und habe 3 Mal aufgesockt gestern zu 1,16$ und heute zu 1,39 und 1,55$ mal schauen was morgen geht werde wenn möglich bei 1,8-1,9$ die teuren Nachkäufe wieder abstoßen und mit dem Rest dabeibleiben.

LG Printi

[sebirem]

ich denke du machst das Richtige!

Das gestrige Volumen haut mich um, spitze!
28,588,630 sowie after-hours 333,358
Der Kurs KANN hier deutlich höher gehen!


sind zwar im überkauften Bereich, aber das interessiert momentan nicht!
Lass wir uns überraschen!

[printguru]

Vorbörslich schaut es schonmal gut aus 1,68-1,7$ denke aber das kann bis zur Eröffnung noch ordentlich hochgehen....


Bleibt spannend.


LG Printi

[pjone]

http://seekingalpha.com/article/1467361-we-are-witnessing-ei…

[printguru]

Antwort auf Beitrag Nr.: 44.745.291 von sebirem am 30.05.13 07:16:35

sieht gut aus heute und dazu noch diese klasse News

[sebirem]

Antwort auf Beitrag Nr.: 44.751.977 von printguru am 30.05.13 19:15:41

habe noch KEINE Stücke hergegeben, hoffe wir etablieren uns im Bereich über 2$ nach den NEWS!!
http://finance.yahoo.com/news/celsion-announces-thermodox-he…

denke hier kanns ähnlich wie bei VRML laufen mit dem Anstieg!
Dabeibleiben!
Hammer vOLUMEN!

[printguru]

Antwort auf Beitrag Nr.: 44.752.145 von sebirem am 30.05.13 19:31:39

bin vorerst komplett raus da stimmt doch etwas nicht....
So ein Hammervolumen und so eine supper Meldung und was macht der Kurs er bewegt sich kaum?????
Da wurden heute viele in die Aktie gelockt und abgefüttert nungut war ein fetter Gewinn und ich denke ich komme bald wieder zu 1,1-1,2$ rein....

Bin zufrieden aber aufgrund der Reaktion der Aktie trotz der News enttäuscht


LG Printi

[franzisca]

Antwort auf Beitrag Nr.: 44.753.375 von printguru am 30.05.13 21:43:30

Celsion Corporation After Hours Trading
$1.97
*
0.21
negative
11.93%

*Delayed - data as of 05/30/2013 18:02

Read more: http://www.nasdaq.com/symbol/clsn/after-hours#ixzz2UoeyPvE6

[franzisca]

http://www.schaeffersresearch.com/marketcenters/optionscente…

[printguru]

Schlußkurs 1,69$ war wohl nichts.....bin froh ersteinmal Kasse gemacht zu haben

werde versuchen bei 1,4$ wieder erste kleinere Positionen aufzubauen vieleicht klappts....


LG Printi

[sebirem]

mist....
zu spät. Ein dicken rums nach unten.
Jetzt lohnt der Einstieg für mich erst wieder unter 1$

[sebirem]

Antwort auf Beitrag Nr.: 44.831.001 von sebirem am 11.06.13 23:29:30

... freue mich wenigstens über ein bißchen Profit.

Schade, dass bei der ThermoDox Heat III Studie keine Hoffnung besteht!
Ärzte sagen "keine Hoffnung auf Zulassung"
Außerdem Cashburn- Rate zu hoch um die dritte Phase mit erneuter Forschung zu realisieren!

SeekingAlpha Artikel!!
http://seekingalpha.com/article/1495002-celsion-50-downside-…


Ich weiß man vergleicht keine Aktien aus unterschiedlichen Branchen, aber
ich sehe wie bei Delcath Systems parallelen!
Der Kurs wir absacken OHNE Fantasie!

Na ja, seit ihr noch drin?

[zeitfenster]

Antwort auf Beitrag Nr.: 44.831.643 von sebirem am 12.06.13 08:22:24

ließ mal den hier und denke Dir Deinen Teil!
http://seekingalpha.com/article/1496322-6-new-bearish-celsio…

[printguru]

bin froh die Teile so teuer losgeworden zu sein und werde vorerst auch nicht wieder einsteigen ist mir zu heiß glaube da geht nichts mehr.....Schade


LG Printi